- Home
- WRB vs ROIV Comparison
WRB vs ROIV Comparison
Compare WRB & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WRB | ROIV |
|---|---|---|
| Founded | 1967 | 2014 |
| Country | United States | United Kingdom |
| Employees | 8804 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7B | 20.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | WRB | ROIV |
|---|---|---|
| Price | $64.69 | $26.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 8 |
| Target Price | ★ $70.71 | $27.56 |
| AVG Volume (30 Days) | 1.7M | ★ 4.4M |
| Earning Date | 04-21-2026 | 02-06-2026 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,053,000.00 |
| Revenue This Year | $5.06 | N/A |
| Revenue Next Year | $4.80 | $594.84 |
| P/E Ratio | $15.91 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $62.63 | $8.73 |
| 52 Week High | $78.96 | $30.33 |
Technical Indicators
Market Signals| Indicator | WRB | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 31.96 | 42.52 |
| Support Level | N/A | $20.46 |
| Resistance Level | $73.41 | $27.94 |
| Average True Range (ATR) | 1.19 | 0.88 |
| MACD | -0.38 | -0.38 |
| Stochastic Oscillator | 16.79 | 1.04 |
Price Performance
Historical ComparisonAbout WRB W.R. Berkley Corporation
W.R. Berkley is an insurance holding company with a host of subsidiaries that primarily underwrite commercial casualty insurance. The firm specializes in niche products that include various excess and surplus lines, workers' compensation insurance, self-insurance consulting, reinsurance, and regional commercial lines for small and midsize businesses.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.